Basic and clinical research for therapeutic angiogenesis of the next generation

为了将糖链应用于心血管疾病的再生药物，我们将N-乙酰氨基葡萄糖(GlcNAc)修饰的脂质体静脉注射到小鼠血管损伤模型中，发现GlcNAc-脂质体在血管损伤部位特异性积聚。此外，我们使用脂肪组织来源的干细胞(ADRC)开始了一项新的治疗性血管生成，与使用骨髓细胞的血管重建治疗相比，ADRC具有更小的侵入性。

To apply the sugar chain for regenerative medicine of cardiovascular diseases, we administered N-acetyl glucosamine (GlcNAc)-modified liposome intravenously to the vascular injury model of mice, and found that GlcNAc-liposome was accumulated specifically in the vascular injury site. In addition, we started a new therapeutic angiogenesis using adipose tissue-derived stem cells (ADRC), which is less invasive compared to revascularization therapy using bone marrow cells.